While others have reported on the significant MACE reduction with GLP-1RA therapy in the secondary prevention cohort, but not in the primary prevention setting [91], our findings extend the current notion that the beneficial impact on the individual MACE constituents, particularly MI risk reduction, may be attenuated in the higher risk secondary preventative population with established CVD, often characterized by advanced age and multimorbidity status [90]
More recently, we reviewed five additional products and tested three powders
Akkermansia is not a replacement for GLP-1 medications, but it may help support the gut conditions tied to natural metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience
Before performing docking experiments, we utilized the PSN-ENM method to gain a comprehensive understanding of the distinct characteristics and similarities between MRP1 and MRP7 and to reveal the unique binding modes of these two proteins